EUVIMEDEUVIMED entdecken
Crossref

Cell line development and bioreactor process optimization for an atezolizumab biosimilar

Ayca Zeybek Kuyucu, Dogu Sayili, Ridvan Orkut, Olcay Mert, İbrahim Oguzhan Tarman, Busra Lulaci, Ali Mert Sencer, Asli Kurden Pekmezci, Mehmet Ender Avci, Sibel Kalyoncu iD, Mehmet Inan iD

Biotechnology and Applied Biochemistry · 2025

DOI: 10.1002/bab.2704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Ayca Zeybek Kuyucu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Izmir Biomedicine and Genome Center, Izmir, Turkey. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Bioreactors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Scientific and Technological Research Council of Türkiye.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint inhibitors are widely recognized immunotherapeutic drugs, known for their effectiveness in treating various cancers. Atezolizumab, targeting the immune checkpoint programmed death‐ligand 1, is successfully used to treat several types of cancers. Atezolizumab is a potential biosimilar candidate due to its huge success in the clinic but there is no literature on its production process in mammalian cells. In this study, we generated a monoclonal cell line derived from recombinant Chinese hamster ovary DG44 cells to produce atezolizumab. The selected single clone was employed for media screening and process development. Following production in a 7‐L bioreactor, atezolizumab was purified using a three‐step chromatographic method. Finally, the purified atezolizumab was characterized and compared with commercial atezolizumab (Tecentriq) through several chromatographic and kinetics analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsBioreactorsAntibodies, Monoclonal, HumanizedCricetulusAnimalsCHO CellsHumansCricetinae

Stichwörter der Autor:innen

atezolizumabbioprocess engineeringbiosimilarcancermonoclonal antibody

Substanzen

Biosimilar PharmaceuticalsAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Izmir Biomedicine and Genome Center, Izmir, Turkey.
  • Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey.
  • Rectorate, Dokuz Eylul University, Izmir, Turkey.
  • Department of Food Engineering, Akdeniz University, Antalya, Turkey.

ORCID-Profile: Sibel Kalyoncu, Mehmet Inan

Förderung

  • Scientific and Technological Research Council of Türkiye

Zitieren

APA

Kuyucu, A. Z., Sayili, D., Orkut, R., Mert, O., Tarman, İ. O., Lulaci, B., Sencer, A. M., Pekmezci, A. K., Avci, M. E., Kalyoncu, S., & Inan, M. (2025). Cell line development and bioreactor process optimization for an atezolizumab biosimilar. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2704

Vancouver

Kuyucu AZ, Sayili D, Orkut R, Mert O, Tarman İO, Lulaci B, et al. Cell line development and bioreactor process optimization for an atezolizumab biosimilar. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2704

BibTeX
@article{Kuyucu2025,
  author = {Kuyucu, Ayca Zeybek and Sayili, Dogu and Orkut, Ridvan and Mert, Olcay and Tarman, İbrahim Oguzhan and Lulaci, Busra and Sencer, Ali Mert and Pekmezci, Asli Kurden and Avci, Mehmet Ender and Kalyoncu, Sibel and Inan, Mehmet},
  title = {Cell line development and bioreactor process optimization for an atezolizumab biosimilar},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2025},
  doi = {10.1002/bab.2704}
}
Kostenlos starten →